Loomis, Sayles & Company’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Loomis, Sayles & Company’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-146,783	Closed	-$22.9M	–	741
2020 Q2	$22.9M	Buy	146,783 +12,894	+10%	+$1.96M	0.04%	198
2020 Q1	$19.3M	Buy	133,889 +17,909	+15%	+$3.46M	0.04%	170
2019 Q4	$23.7M	Sell	115,980 -105,803	-48%	-$19.3M	0.04%	189
2019 Q3	$17.8M	Buy	221,783 +25,194	+13%	+$2.14M	0.03%	228
2019 Q2	$18.5M	Buy	+196,589	New	+$17M	0.03%	218

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Loomis, Sayles & Company's RETA Position: Q3 2020 in Review

Loomis, Sayles & Company sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 146,783 shares — an estimated $22.9M sold.

Loomis, Sayles & Company first reported a position in RETA in Q2 2019 and held it in 5 quarters. The position peaked at $23.7M in Q4 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

Loomis, Sayles & Company reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
Loomis, Sayles & Company sold 146,783 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $22.9M.
Loomis, Sayles & Company first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 5 quarters.
Loomis, Sayles & Company's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $23.7M in Q4 2019.
186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Loomis, Sayles & Company's 13F filing for Q3 2020, filed 12 Nov 2020.